Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate
  • Clinical Data

Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate

BioSpace

If Biogen has shown that tau can impact cognition, Denali's technology--validated with an FDA approval in Hunter syndrome--could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

pharminent May 15, 2026

BioSpace

If Biogen has shown that tau can impact cognition, Denali’s technology–validated with an FDA approval in Hunter syndrome–could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Genmab drops 2 antibody assets, including another ProfoundBio ADC
Next: ECO 2026: tirzepatide shows potential for T1D treatment

Related Stories

  • Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

pharminent June 5, 2026
  • Clinical Data

ADC Therapeutics slumps on cancer drug safety scare

pharminent June 4, 2026
  • Clinical Data

Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity

pharminent June 4, 2026

You May Have Missed

  • Commercial

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

pharminent June 5, 2026
  • Market Access

Medicare Advantage in 2026: Enrollment Update and Key Trends

pharminent June 5, 2026
  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

pharminent June 5, 2026
  • Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

pharminent June 5, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.